Samrat Pharmachem Limited (BOM:530125)
India · Delayed Price · Currency is INR 243.45
-8.50 (-3.37%)
At close: Jul 31, 2026
Samrat Pharmachem Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 59.97 | 0.48 | 96.68 | 118.62 | 147.05 |
Short-Term Investments | 3.68 | 3.6 | 0.11 | 0.14 | 0.1 |
Cash & Short-Term Investments | 63.65 | 4.08 | 96.78 | 118.76 | 147.15 |
Cash Growth | 1460.48% | -95.78% | -18.50% | -19.29% | 487.00% |
Accounts Receivable | 510.48 | 565.36 | 692.78 | 516.75 | 435.75 |
Other Receivables | 0.17 | 0.18 | 0.2 | 0.18 | 0.31 |
Receivables | 510.65 | 565.54 | 692.97 | 516.93 | 436.2 |
Inventory | 436.23 | 380.05 | 206.77 | 325.28 | 124.16 |
Prepaid Expenses | - | 1.69 | 0.49 | 0.4 | 0.17 |
Other Current Assets | 27.34 | 82.25 | 28.66 | 29.17 | 4.93 |
Total Current Assets | 1,038 | 1,034 | 1,026 | 990.53 | 712.61 |
Property, Plant & Equipment | 128.26 | 104.65 | 107.16 | 106.95 | 99.77 |
Long-Term Investments | 35.03 | 69.02 | 69.78 | 59.26 | 25.63 |
Other Intangible Assets | 0.12 | 0.15 | 0.07 | 0.08 | 0.09 |
Other Long-Term Assets | 39.77 | 4.79 | 11.83 | 6.65 | 5.97 |
Total Assets | 1,244 | 1,215 | 1,217 | 1,166 | 846.12 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 426.64 | 385.62 | 476.68 | 318.8 | 233.92 |
Accrued Expenses | - | 0.76 | 1.21 | 0.49 | 8.9 |
Short-Term Debt | 107.07 | 99.15 | 84.55 | 186.59 | 75.2 |
Current Income Taxes Payable | - | 9.41 | - | 21.35 | 55.28 |
Other Current Liabilities | 24.53 | 0.89 | 1.59 | 4.67 | - |
Total Current Liabilities | 558.25 | 495.83 | 564.03 | 531.91 | 373.29 |
Long-Term Deferred Tax Liabilities | 4.12 | 1.11 | 3.36 | 2.54 | 4.61 |
Total Liabilities | 562.37 | 496.94 | 567.39 | 534.45 | 377.9 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 30.9 | 30.9 | 30.9 | 30.9 | 30.9 |
Retained Earnings | - | - | - | 600.54 | 437.32 |
Comprehensive Income & Other | 650.9 | 687.11 | 619.07 | - | - |
Shareholders' Equity | 681.79 | 718 | 649.97 | 631.43 | 468.22 |
Total Liabilities & Equity | 1,244 | 1,215 | 1,217 | 1,166 | 846.12 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 107.07 | 99.15 | 84.55 | 186.59 | 75.2 |
Net Cash (Debt) | -43.42 | -95.07 | 12.24 | -67.83 | 71.95 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -14.05 | -30.77 | 3.96 | -21.95 | 23.29 |
Filing Date Shares Outstanding | 3.09 | 3.09 | 3.09 | 3.09 | 3.09 |
Total Common Shares Outstanding | 3.09 | 3.09 | 3.09 | 3.09 | 3.09 |
Working Capital | 479.62 | 537.78 | 461.65 | 458.62 | 339.32 |
Book Value Per Share | 220.65 | 232.39 | 210.37 | 204.37 | 151.54 |
Tangible Book Value | 681.67 | 717.86 | 649.9 | 631.36 | 468.13 |
Tangible Book Value Per Share | 220.61 | 232.34 | 210.35 | 204.34 | 151.51 |
Land | - | 0.89 | 0.89 | 0.89 | 0.89 |
Buildings | - | 63.29 | 63.29 | 63.29 | 63.29 |
Machinery | - | 103.34 | 101.1 | 97.46 | 83.86 |